Fees payable to the European Medicines Agency: Other fees and charges for medicinal products for human use, veterinary medicinal products and consultations on medical devices

Human medicines European public assessment report (EPAR): Evotaz, atazanavir,cobicistat, Date of authorisation: 13/07/2015, Revision: 15, Status: Authorised

Dronedarone film-coated tablets 400 mg product-specific bioequivalence guidance - Revision 1

Dronedarone product-specific bioequivalence guidance

Ledipasvir/sofosbuvir product-specific bioequivalence guidance

Ledipasvir/sofosbuvir film-coated tablet 45 mg/200 mg and 90 mg/400 mg, coated granules 33.75mg/150mg and 45mg/200mg product-specific bioequivalence guidance - Revision 1

EMEA-003549-PIP01-23

EMEA-003616-PIP01-24

EMEA-003521-PIP01-23

EMEA-003513-PIP01-23